Transfusion Medicine: Blood Products, Reactions, and Compatibility Testing

Transfusion medicine encompasses the safe collection, processing, testing, storage, and administration of blood and blood components. This field represents a critical intersection of hematology, immunology, and clinical medicine, requiring thorough understanding of blood group systems, compatibility testing, and adverse reaction management.

Blood Components Overview:

Blood can be separated into various components, each serving specific therapeutic purposes:

Blood Group Systems:

The ABO system, discovered by Karl Landsteiner, remains the most clinically significant blood group system. It consists of four main blood types based on the presence or absence of A and B antigens on red blood cell surfaces, along with corresponding antibodies in plasma.

• Type A: A antigen present, anti-B antibodies
• Type B: B antigen present, anti-A antibodies
• Type AB: Both A and B antigens, no antibodies (universal recipient for plasma)
• Type O: No antigens, both anti-A and anti-B antibodies (universal donor for RBCs)

The Rh system, particularly the D antigen, represents the second most important blood group system. Rh-positive individuals express the D antigen, while Rh-negative individuals lack it. Unlike ABO antibodies, anti-D antibodies are not naturally occurring and develop only after exposure through transfusion or pregnancy.

Clinical Significance:

Understanding blood group compatibility is essential for preventing hemolytic transfusion reactions, which can be fatal. The principle of compatibility requires that donor red blood cells must not react with recipient antibodies, and donor antibodies should not react with recipient antigens. This forms the foundation for all compatibility testing protocols used in blood banks worldwide.

Modern transfusion medicine emphasizes component therapy, allowing targeted treatment while conserving blood resources and minimizing exposure risks. Each blood component has specific indications, contraindications, and administration guidelines.

Red Blood Cell Concentrates:

Packed red blood cells (PRBCs) represent the most commonly transfused component, with specific indications including:

• Hemoglobin <7 g/dL (70 g/L) in stable patients
• Hemoglobin <8-10 g/dL (80-100 g/L) in patients with cardiovascular disease
• Active bleeding with hemodynamic instability
• Symptomatic anemia unresponsive to other treatments

One unit of PRBCs typically increases hemoglobin by 1 g/dL (10 g/L) and hematocrit by 3% in adults. PRBCs are stored in additive solutions containing adenine, glucose, and mannitol, extending shelf life to 42 days at 4°C.

Platelet Concentrates:

Platelet transfusions are indicated for:

• Thrombocytopenia with active bleeding
• Platelet count <10,000/μL (10 × 10⁹/L) prophylactically
• Platelet count <50,000/μL (50 × 10⁹/L) before invasive procedures
• Qualitative platelet defects with bleeding

Platelet products include pooled random donor platelets and single-donor apheresis platelets. One apheresis unit or 4-6 pooled units should increase platelet count by 30,000-60,000/μL (30-60 × 10⁹/L).

Fresh Frozen Plasma (FFP):

FFP contains all coagulation factors and is indicated for:

• Multiple coagulation factor deficiencies
• Reversal of warfarin anticoagulation (when vitamin K inadequate)
• Massive transfusion protocol
• Thrombotic thrombocytopenic purpura (plasma exchange)

Typical dosing is 10-15 mL/kg, expecting to increase coagulation factor levels by 15-20%.

Cryoprecipitate:

Cryoprecipitate is rich in fibrinogen, factor VIII, factor XIII, and von Willebrand factor. Primary indications include:

• Fibrinogen deficiency (levels <100 mg/dL or 1.0 g/L)
• Von Willebrand disease (when DDAVP contraindicated)
• Factor XIII deficiency
• Massive transfusion with hypofibrinogenemia

Specialized Products:

Additional products include granulocyte concentrates for severe neutropenia with infections, immunoglobulins for immune deficiencies, and factor concentrates for specific coagulation disorders. Irradiated blood products prevent transfusion-associated graft-versus-host disease in immunocompromised patients.

Compatibility testing forms the cornerstone of safe transfusion practice, designed to detect clinically significant antibodies that could cause hemolytic transfusion reactions. This multi-step process ensures optimal patient safety through systematic screening and crossmatching procedures.

Pre-transfusion Testing Protocol:

1. ABO/Rh Typing: Determines patient's blood group using anti-A, anti-B, and anti-D antisera
2. Antibody Screening: Detects unexpected antibodies using commercially prepared screening cells
3. Crossmatching: Tests compatibility between donor cells and recipient serum
4. Historical Record Review: Checks for previous typing discrepancies or antibodies

Types of Crossmatching:

Antibody Identification:

When antibody screening is positive, comprehensive identification is required using a panel of phenotyped red blood cells. Common clinically significant antibodies include:

• Anti-D, -C, -E, -c, -e (Rh system)
• Anti-K (Kell system)
• Anti-Fya, -Fyb (Duffy system)
• Anti-Jka, -Jkb (Kidd system)
• Anti-S, -s (MNS system)

Special Considerations:

Cold Antibodies: Anti-I, anti-i, and anti-P1 are typically reactive at temperatures below 37°C and usually clinically insignificant. However, high-titer cold agglutinins can cause hemolysis and require specialized testing.

Autoantibodies: Warm autoantibodies can mask clinically significant alloantibodies, requiring adsorption studies to reveal underlying specificities. This process may delay compatibility testing significantly.

Historical Antibodies: Previously identified antibodies may become undetectable but can cause delayed hemolytic transfusion reactions. Maintaining detailed antibody histories is crucial for patient safety.

Quality Assurance:

Compatibility testing laboratories must maintain strict quality control measures, including daily equipment calibration, reagent validation, and proficiency testing. Any discrepancies in testing results require investigation and resolution before blood product release.

Massive Transfusion Considerations:

During massive transfusion protocols, abbreviated compatibility testing may be necessary. Type-specific blood can be released with abbreviated crossmatching, while O-negative blood serves as the universal donor for emergency situations when patient type is unknown.

Transfusion reactions represent serious complications that can range from mild allergic responses to life-threatening hemolytic reactions. Prompt recognition, appropriate management, and thorough investigation are essential for patient safety and future transfusion planning.

Classification of Transfusion Reactions:

Immune-Mediated Reactions:

1. Acute Hemolytic Transfusion Reactions (AHTR):

   • Mechanism: ABO incompatibility causing intravascular hemolysis
   • Onset: Within minutes to hours
   • Symptoms: Fever, chills, back pain, hemoglobinuria, shock
   • Mortality rate: 1:600,000-1:1,000,000 transfusions

2. Delayed Hemolytic Transfusion Reactions (DHTR):

   • Mechanism: Secondary immune response to minor blood group antigens
   • Onset: 3-21 days post-transfusion
   • Symptoms: Fever, mild jaundice, decreased hemoglobin
   • Often subclinical with laboratory evidence only

3. Febrile Non-Hemolytic Transfusion Reactions (FNHTR):

   • Mechanism: Cytokine accumulation or anti-HLA/HPA antibodies
   • Symptoms: Temperature rise ≥1°C, chills without hemolysis
   • Most common reaction type (0.1-1% of transfusions)

4. Allergic Reactions:

   • Mild: Urticaria, pruritis without systemic symptoms
   • Severe: Anaphylaxis with bronchospasm, hypotension, laryngeal edema
   • Mechanism: IgE-mediated hypersensitivity to plasma proteins

Non-Immune Reactions:

1. Transfusion-Related Acute Lung Injury (TRALI):

   • Leading cause of transfusion-related fatalities
   • Onset: Within 6 hours of transfusion
   • Pathophysiology: Anti-HLA or anti-HNA antibodies causing neutrophil activation
   • Clinical features: Acute respiratory distress, bilateral pulmonary infiltrates

2. Transfusion-Associated Circulatory Overload (TACO):

   • Mechanism: Volume overload in patients with compromised cardiac function
   • Risk factors: Elderly patients, heart failure, renal insufficiency
   • Prevention: Slower transfusion rates, diuretic use

Management Protocol:

Immediate Actions:

1. Stop transfusion immediately
2. Maintain IV access with normal saline
3. Check patient identification and blood product compatibility
4. Monitor vital signs and urine output
5. Notify blood bank and attending physician

Laboratory Investigation:

• Post-transfusion blood sample for direct antiglobulin test (DAT)
• Plasma hemoglobin and haptoglobin levels
• Urinalysis for hemoglobinuria
• Repeat ABO/Rh typing and crossmatch
• Blood and urine cultures if bacterial contamination suspected

Treatment Strategies:

Documentation and Reporting: All suspected transfusion reactions require comprehensive documentation and reporting to relevant authorities. Serious adverse events must be reported to blood collection agencies and regulatory bodies for trend analysis and prevention strategies.

Massive transfusion protocol (MTP) represents a coordinated, multidisciplinary approach to managing patients requiring large-volume blood product replacement. The protocol aims to prevent exsanguination while minimizing complications associated with massive blood loss and resuscitation.

Definition and Triggers:

Massive transfusion is traditionally defined as:

• Transfusion of ≥10 units of red blood cells within 24 hours
• Replacement of one blood volume within 24 hours
• Transfusion of ≥4 units of red blood cells within 1 hour with ongoing bleeding

MTP activation triggers include:

• Systolic blood pressure <90 mmHg with active bleeding
• Heart rate >120 bpm with suspected blood loss
• Penetrating torso injury
• Positive FAST exam with hemodynamic instability
• Clinical suspicion of >30% blood volume loss

Balanced Resuscitation Strategy:

Modern MTP emphasizes balanced resuscitation with fixed ratios of blood components, moving away from traditional crystalloid-heavy approaches. The optimal ratio remains debated, but current evidence supports:

Recommended Ratios:

• RBC:FFP:Platelets = 1:1:1 (preferred)
• Alternative ratios: 2:1:1 or 3:2:1
• Early fibrinogen replacement with cryoprecipitate

MTP Implementation:

Phase 1 (Initial Response):

• Activate MTP and alert blood bank
• Obtain type-specific or O-negative blood
• Send baseline laboratories: CBC, coagulation studies, fibrinogen
• Establish large-bore IV access
• Begin warming measures

Phase 2 (Ongoing Resuscitation):

• Continue balanced blood product administration
• Monitor laboratory parameters every 30-60 minutes
• Adjust ratios based on point-of-care testing
• Address metabolic complications

Laboratory Monitoring:

Complications of Massive Transfusion:

Metabolic Complications:

• Hypothermia: Contributes to coagulopathy and cardiac dysfunction
• Acidosis: Worsens coagulopathy and cardiac contractility
• Hypocalcemia: From citrate anticoagulant binding calcium
• Hyperkalemia: From hemolysis and cellular breakdown

Coagulation Abnormalities:

• Dilutional coagulopathy from crystalloid administration
• Platelet dysfunction from hypothermia and acidosis
• Fibrinolysis activation
• Consumption of coagulation factors

Prevention Strategies:

• Minimize crystalloid use during initial resuscitation
• Implement early blood product administration
• Maintain normothermia with warming devices
• Use point-of-care coagulation testing (TEG/ROTEM)
• Consider adjunct therapies: tranexamic acid, factor concentrates

Protocol Termination: MTP should be discontinued when:

• Bleeding is surgically controlled
• Hemodynamic stability achieved
• Laboratory parameters normalize
• Clinical improvement evident

Successful MTP implementation requires regular training, clear communication protocols, and continuous quality improvement based on outcome data and patient mortality reviews.

Transfusion medicine encompasses numerous special situations requiring modified approaches to ensure patient safety and optimal outcomes. These scenarios involve unique patient populations, specific clinical conditions, and emerging technologies that impact transfusion practices.

Pediatric Transfusion Considerations:

Pediatric patients require specialized transfusion approaches due to developmental differences and unique physiologic considerations:

Volume Calculations:

• Blood volume: 70-80 mL/kg in newborns, 70 mL/kg in children
• Transfusion volumes: 10-15 mL/kg for RBCs, 10-20 mL/kg for FFP
• Maximum single transfusion: 20 mL/kg to prevent volume overload

Product Selection:

• CMV-negative products for premature infants
• Irradiated products to prevent TA-GVHD
• Fresh products (<14 days) for neonates to minimize potassium load
• Washed products for patients with previous severe allergic reactions

Maternal-Fetal Medicine:

Hemolytic Disease of the Newborn (HDN): Results from maternal antibodies crossing placental barrier and destroying fetal red blood cells. Most commonly involves anti-D, but can include other antibodies:

• Prevention: RhIg administration to Rh-negative mothers
• Management: Intrauterine transfusion, exchange transfusion
• Product selection: Antigen-negative, compatible with maternal antibodies

Perioperative Considerations:

Patient Blood Management (PBM): Comprehensive approach to optimize patient outcomes through:

1. Preoperative Optimization:

   • Iron deficiency correction
   • Anemia treatment
   • Medication review (anticoagulants)
   • Autologous blood donation (selected cases)

2. Intraoperative Strategies:

   • Cell salvage techniques
   • Acute normovolemic hemodilution
   • Controlled hypotension
   • Point-of-care coagulation monitoring

3. Postoperative Management:

   • Restrictive transfusion thresholds
   • Iron supplementation
   • Minimizing blood loss from phlebotomy

Immunocompromised Patients:

Product Modifications:

• Irradiated products: Prevent TA-GVHD in susceptible patients
• CMV-negative products: Reduce transmission risk
• Leukoreduced products: Minimize alloimmunization and cytokine reactions

High-Risk Groups:

• Hematologic malignancy patients
• Solid organ transplant recipients
• Bone marrow transplant patients
• Patients receiving chemotherapy
• Congenital immunodeficiencies

Religious and Cultural Considerations:

Jehovah's Witnesses: Refusal of blood transfusion based on religious beliefs requires:

• Clear documentation of informed consent/refusal
• Discussion of acceptable alternatives
• Multidisciplinary team approach
• Blood conservation strategies

Acceptable alternatives may include:

• Autologous techniques (varying acceptance)
• Blood substitutes and pharmacologic agents
• Aggressive blood conservation measures

Emerging Technologies:

Pathogen Reduction Technologies:

• Photochemical treatment to inactivate pathogens
• Reduces risk of bacterial, viral, and parasitic transmission
• Currently available for platelets and plasma
• Under development for red blood cells

Artificial Blood Substitutes:

• Hemoglobin-based oxygen carriers (HBOCs)
• Perfluorocarbon emulsions
• Still investigational with limited clinical applications

Quality and Safety Initiatives:

Hemovigilance Systems:

• Systematic surveillance of adverse transfusion events
• Data collection for trend analysis
• Implementation of preventive measures
• Continuous quality improvement

Two-Patient Identification:

• Mandatory dual verification before transfusion
• Bedside compatibility confirmation
• Electronic identification systems
• Error reduction strategies